NDAORALTABLETPriority Review
Lifecycle
Pre-Launch
Data completeness
2/8 — Basic
Priority Review
STAVUDINE; LAMIVUDINE; NEVIRAPINE (stavudine; lamivudine; nevirapine) by PharmaIN is 12. Approved for human immunodeficiency virus (hiv)-1 infection [see ].
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STAVUDINE; LAMIVUDINE; NEVIRAPINE is a triple-agent nucleoside/non-nucleoside reverse transcriptase inhibitor (NRTI/NNRTI) combination for HIV-1 infection. Stavudine is rapidly absorbed with a short half-life (~2.3 hours) and minimal protein binding, distributing equally between red blood cells and plasma. This fixed-dose combination targets treatment-naïve and treatment-experienced HIV-1 patients requiring multi-drug antiretroviral therapy.
Pre-Launch
Pre-launch stage suggests active team building in commercial, regulatory, and manufacturing roles; career trajectory depends heavily on approval timing and market adoption in resource-limited settings where this combination remains relevant.
Mechanism of Action
12.1 Mechanism of Action Stavudine is an antiviral drug [see ]. 12.3 Pharmacokinetics The pharmacokinetics of stavudine have been evaluated in HIV-1-infected adult and pediatric patients (, , and ). Peak plasma concentrations (C max ) and area under the plasma concentration-time curve (AUC)…
Worked on STAVUDINE; LAMIVUDINE; NEVIRAPINE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.